The Future of Targeted Therapies in Ovarian Cancer

被引:43
作者
Banerjee, Susana [1 ]
Gore, Martin [1 ]
机构
[1] Royal Marsden Hosp, London SW3 6JJ, England
关键词
Ovarian cancer; Targeted therapy; VEGF inhibitors; PARP inhibitors; ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; METASTATIC COLORECTAL-CANCER; PRIMARY PERITONEAL CARCINOMA; TYROSINE KINASE INHIBITOR; EPITHELIAL OVARIAN; RECURRENT OVARIAN; PROGNOSTIC-SIGNIFICANCE; FACTOR EXPRESSION; MESSENGER-RNA;
D O I
10.1634/theoncologist.2009-0013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is the second most common gynecological malignancy and the leading cause of death from gynecological cancer. Most women present with advanced disease with little prospect for cure. There have been some advances in surgical and chemotherapeutic strategies, but these approaches have led to only minor improvements in outcome. There remains a significant risk for recurrence and resistance to therapy, and hence there is a need to improve upon the current treatment options. Molecularly directed therapy aims to target tumor cells and the tumor microenvironment by blocking specific molecular changes in the cancer. The most promising agents so far are the antiangiogenic agents and polyadenosine diphosphate-ribose polymerase inhibitors. This article reviews the various targeted therapeutic approaches under clinical investigation in ovarian cancer and the challenges facing their future success in the clinic. The Oncologist 2009;14:706-716
引用
收藏
页码:706 / 716
页数:11
相关论文
共 85 条
[1]  
[Anonymous], J CLIN ONCOL S
[2]  
[Anonymous], J CLIN ONCOL S
[3]   A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair [J].
Ashworth, Alan .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3785-3790
[4]  
Audeh MW, 2009, J CLIN ONCOL, V27
[5]   Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity [J].
Azad, Nilofer S. ;
Posadas, Edwin M. ;
Kwitkowski, Virginia E. ;
Steinberg, Seth M. ;
Jain, Lokesh ;
Annunziata, Christina M. ;
Minasian, Lori ;
Sarosy, Gisele ;
Kotz, Herbert L. ;
Premkumar, Ahalya ;
Cao, Liang ;
McNally, Deborah ;
Chow, Catherine ;
Chen, Helen X. ;
Wright, John J. ;
Kohn, Elise C. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3709-3714
[6]  
Baldwin RL, 2000, CANCER RES, V60, P5329
[7]   The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer [J].
Bartlett, JMS ;
Langdon, SP ;
Simpson, BJB ;
Stewart, M ;
Katsaros, D ;
Sismondi, P ;
Love, S ;
Scott, WN ;
Williams, ARW ;
Lessells, AM ;
Macleod, KG ;
Smyth, JF ;
Miller, WR .
BRITISH JOURNAL OF CANCER, 1996, 73 (03) :301-306
[8]   Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer [J].
Berek, Jonathan ;
Taylor, Peyton ;
McGuire, William ;
Smith, L. Mary ;
Schultes, Birgit ;
Nicodemus, Christopher F. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) :418-425
[9]   Modes of resistance to anti-angiogenic therapy [J].
Bergers, Gabriele ;
Hanahan, Douglas .
NATURE REVIEWS CANCER, 2008, 8 (08) :592-603
[10]   EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR AND ITS RECEPTORS FLT AND KDR IN OVARIAN-CARCINOMA [J].
BOOCOCK, CA ;
CHARNOCKJONES, DS ;
SHARKEY, AM ;
MCLAREN, J ;
BARKER, PJ ;
WRIGHT, KA ;
TWENTYMAN, PR ;
SMITH, SK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (07) :506-516